By Product
- Metal-based Markers
- Pure Gold
- Gold Alloys
- Other Metal-based Markers
- Polymer-based Markers
- Other Fiducial Markers
By Modality
- CT/CBCT
- MRI
- Ultrasound
- X-Ray
By Application
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Head and Neck Cancer
- Others
By End User
- Hospitals
- Radiotherapy Center
- Academic and Research Center
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
The market is classified into product, modality, application, end user and region. The product segment is categorised into gold combination, polymer, liquid and other metals. The gold segment is predicted to hold the largest fiducial markers market share due to its superior stability and accurate visibility of these products with multiple modalities. Gold fiducial markers, along with the combination of other metals like platinum, nickel and titanium for enhancing their efficiency in visualising the tumors. For example, the gold fiducial markers, in combination with titanium stripes enhance the MRI image visibility. Multiple companies are heavily investing in research and development for designing products with improvements in efficiency. For example, IBA Dosimetry GmbH has announced a pure gold fiducial marker by the name Visicoil which is a helically shaped product that has a hollow core thereby reducing the prevalence of general complications like marker artifacts and migration. The modality segment is categorised into ultrasound, CT/CBCT, MRI and X-ray. The CT/CBCT segment is anticipated to lead the market owing to its ease of integration with current radiotherapy equipment and a low-level dosage exposure shall augment the growth of the segment. The ultrasound modality is predicted to grow at a substantial rate during the forecasted timeframe. This modality has a lower radiation toxicity as compared to other imaging modalities is a crucial factor for the proliferation of the market.
The application segment is categorised into prostate, breast and lung cancer. The prostate cancer segment is predicted to lead the market owing to the rising acceptance of prostate cancer treatment across the world. Increased prevalence of lung cancer and advancements in technology for developing enhanced fiducial markers for an effective treatment of the disease. The end user segment is divided into radiotherapy centres, hospitals and academic research centres. The hospitals segment is anticipated to lead the market owing to the availability of novel radiotherapy equipment in healthcare institutes and rise in the number of multispecialty hospitals.
The North America region is expected to dominate the market owing to improvements in the reimbursement policies, an impounding presence of key market players and rise in the number of awareness initiatives undertaken by government bodies. Furthermore, increased acceptance of novel imaging modalities and radiotherapy procedures shall propel the growth of the market.